Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Neflamapimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
    CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

    08 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/08/2977725/0/en/CervoMed-Awarded-the-Prix-Galien-USA-2024-Prize-for-Best-Startup.html

    GLOBENEWSWIRE
    08 Nov 2024
    Share Share
    CervoMed Announces Last Patient Visit In Phase 2b RewinD-LB Trial
    CervoMed Announces Last Patient Visit In Phase 2b RewinD-LB Trial

    15 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/15/2963137/0/en/CervoMed-Announces-Last-Patient-Last-Visit-in-Phase-2b-RewinD-LB-Trial-of-Neflamapimod-for-the-Treatment-of-Early-Stage-Dementia-with-Lewy-Bodies-DLB.html

    GLOBENEWSWIRE
    15 Oct 2024
    Share Share
    CervoMed To Present Neflamapimod Biomarker Data In DLB At AAIC 2024
    CervoMed To Present Neflamapimod Biomarker Data In DLB At AAIC 2024

    29 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/29/2920251/0/en/CervoMed-Announces-Presentation-at-AAIC-2024-on-Plasma-Biomarker-Data-That-Are-Consistent-with-Neflamapimod-Impacting-the-Underlying-Disease-Process-in-Patients-with-Dementia-with-.html

    GLOBENEWSWIRE
    29 Jul 2024
    Share Share
    CervoMed To Host KOL Event On Neflamapimod For Lewy Body Dementia
    CervoMed To Host KOL Event On Neflamapimod For Lewy Body Dementia

    11 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/11/2911837/0/en/CervoMed-to-Host-Virtual-KOL-Event-on-Neflamapimod-for-Dementia-with-Lewy-Bodies-on-July-23-2024.html

    GLOBENEWSWIRE
    11 Jul 2024
    Share Share
    CervoMed Completion Pha 2b RewinD-LB Clinical Trial of Neflamapimod
    CervoMed Completion Pha 2b RewinD-LB Clinical Trial of Neflamapimod

    11 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/11/2896702/0/en/CervoMed-Announces-Completion-of-Enrollment-in-Phase-2b-RewinD-LB-Clinical-Trial-of-Neflamapimod-for-the-Treatment-of-Patients-with-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    11 Jun 2024
    Share Share
    EIP Pharma Announces First Patient Dosed in Ph 2b Trial Evaluating Neflamapimod
    EIP Pharma Announces First Patient Dosed in Ph 2b Trial Evaluating Neflamapimod

    14 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eip-pharma-announces-first-patient-dosed-in-rewind-lb-phase-2b-clinical-trial-evaluating-neflamapimod-in-dementia-with-lewy-bodies-301899140.html

    PR NEWSWIRE
    14 Aug 2023
    Share Share